Meisner Lara
Insider CIK 1883986 · VRDN General Counsel and Secretary · BCAX Chief Legal Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics Inc. | A Award deriv | 2026-02-02 | 2026-02-04 | 90,000 | — | $0 | 90,000 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise deriv | 2025-09-29 | 2025-10-01 | 33,807 | — | $0 | 101,423 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | S Sale | 2025-09-29 | 2025-10-01 | 33,807 | $14.75 | $498.7K | 0 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise | 2025-09-29 | 2025-10-01 | 33,807 | $9.24 | $312.4K | 33,807 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise deriv | 2025-09-15 | 2025-09-17 | 9,744 | — | $0 | 87,699 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise deriv | 2025-09-15 | 2025-09-17 | 6,085 | — | $0 | 54,769 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise | 2025-09-15 | 2025-09-17 | 15,829 | $5.45 | $86.3K | 15,829 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | S Sale | 2025-09-15 | 2025-09-17 | 15,829 | $11.49 | $181.9K | 0 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise deriv | 2025-06-16 | 2025-06-18 | 6,085 | — | $0 | 60,854 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise deriv | 2025-06-16 | 2025-06-18 | 9,744 | — | $0 | 97,443 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise | 2025-06-16 | 2025-06-18 | 15,829 | $5.45 | $86.3K | 15,829 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | S Sale | 2025-06-16 | 2025-06-18 | 15,829 | $10.43 | $165.1K | 0 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise deriv | 2025-03-14 | 2025-03-18 | 30,246 | — | $0 | 67,119 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise deriv | 2025-03-14 | 2025-03-18 | 48,720 | — | $0 | 107,187 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | M Exercise | 2025-03-14 | 2025-03-18 | 79,146 | $5.45 | $431.3K | 79,145 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | S Sale | 2025-03-14 | 2025-03-18 | 48,526 | $12.69 | $615.8K | 30,620 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | S Sale | 2025-03-14 | 2025-03-18 | 30,620 | $13.24 | $405.4K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2023-06-16 | 2023-06-20 | 28 | — | $0 | 37,453 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2023-06-16 | 2023-06-20 | 27 | $23.03 | $622 | 29,998 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2023-06-16 | 2023-06-20 | 27 | $28.35 | $765 | 29,971 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2023-06-15 | 2023-06-20 | 2,269 | — | $0 | 37,481 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2023-06-15 | 2023-06-20 | 2,269 | $23.03 | $52.3K | 32,240 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2023-06-15 | 2023-06-20 | 2,269 | $28.02 | $63.6K | 29,971 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2023-06-06 | 2023-06-06 | 5,126 | — | $0 | 84,375 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2023-06-06 | 2023-06-06 | 5,126 | $18.51 | $94.9K | 35,097 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2023-06-06 | 2023-06-06 | 5,126 | $25.02 | $128.3K | 29,971 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2023-06-05 | 2023-06-06 | 499 | — | $0 | 89,501 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2023-06-05 | 2023-06-06 | 499 | $18.51 | $9.2K | 30,470 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2023-06-05 | 2023-06-06 | 499 | $25.03 | $12.5K | 29,971 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2023-06-02 | 2023-06-06 | 1,875 | — | $0 | 18,128 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2023-06-02 | 2023-06-06 | 1,875 | $24.21 | $45.4K | 29,971 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2023-06-02 | 2023-06-06 | 1,875 | $14.00 | $26.3K | 31,846 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2023-03-09 | 2023-03-10 | 29,971 | $29.07 | $871.3K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | A Award deriv | 2023-02-08 | 2023-02-10 | 108,000 | — | $0 | 108,000 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2023-01-23 | 2023-01-25 | 4,971 | — | $0 | 39,750 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2023-01-23 | 2023-01-25 | 1,872 | — | $0 | 20,003 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2023-01-23 | 2023-01-25 | 1,872 | $14.00 | $26.2K | 6,843 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2023-01-23 | 2023-01-25 | 6,843 | $35.66 | $244.0K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2023-01-23 | 2023-01-25 | 4,971 | $23.03 | $114.5K | 4,971 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2022-12-21 | 2022-12-22 | 16,326 | — | $0 | 44,721 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2022-12-21 | 2022-12-22 | 16,326 | $29.19 | $476.6K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2022-12-21 | 2022-12-22 | 16,326 | $23.03 | $376.0K | 16,326 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2022-12-20 | 2022-12-22 | 600 | — | $0 | 61,047 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2022-12-20 | 2022-12-22 | 600 | $28.07 | $16.8K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2022-12-20 | 2022-12-22 | 600 | $23.03 | $13.8K | 600 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2022-12-16 | 2022-12-19 | 1,297 | — | $0 | 61,647 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2022-12-16 | 2022-12-19 | 1,297 | $28.44 | $36.9K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2022-12-16 | 2022-12-19 | 1,297 | $23.03 | $29.9K | 1,297 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2022-12-15 | 2022-12-19 | 300 | — | $0 | 62,944 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2022-12-15 | 2022-12-19 | 300 | $28.08 | $8.4K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2022-12-15 | 2022-12-19 | 300 | $23.03 | $6.9K | 300 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2022-12-14 | 2022-12-14 | 15,656 | — | $0 | 63,244 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2022-12-14 | 2022-12-14 | 15,656 | $28.12 | $440.2K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2022-12-14 | 2022-12-14 | 15,656 | $23.03 | $360.6K | 15,656 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2022-12-12 | 2022-12-14 | 600 | — | $0 | 78,900 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2022-12-12 | 2022-12-14 | 600 | $23.03 | $13.8K | 600 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2022-12-12 | 2022-12-14 | 600 | $28.05 | $16.8K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2022-11-15 | 2022-11-16 | 8,125 | — | $0 | 21,875 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2022-11-15 | 2022-11-16 | 8,125 | $14.00 | $113.8K | 8,125 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | S Sale | 2022-11-15 | 2022-11-16 | 8,125 | $22.05 | $179.2K | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | A Award deriv | 2022-02-02 | 2022-02-03 | 90,000 | — | $0 | 90,000 | SEC↗ |